2,2,4-Trimethyl-6-(6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-4H-benzo[1,4]oxazin-3-one | 117259-82-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: 2,2,4-Trimethyl-6-(6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-4H-benzo[1,4]oxazin-3-one
• 英文别名: 2,2,4-trimethyl-6-(6-oxo-4,5-dihydro-1H-pyridazin-3-yl)-1,4-benzoxazin-3-one
• CAS: 117259-82-2
• 化学式: C₁₅H₁₇N₃O₃
• 分子量: 287.318
• InChiKey: MWEVAXDCRZMUHX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  71
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2,2,4-Trimethyl-2H-1,4-benzoxazin-3(4H)-one 在 三氯化铝 、 一水合肼 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 1.0h， 生成 2,2,4-Trimethyl-6-(6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-4H-benzo[1,4]oxazin-3-one
  参考文献：
  名称：

  Reddy Sastry; Srinivasa Rao; Krishnan, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1989, vol. 28, # 10, p. 882 - 884

  摘要：

  DOI：

文献信息

• 6-Benzoxazinyl- and 6-benzothiazinyl-2,3,4,5-tetrahydropyridazin-3-ones
  申请人：ORTHO PHARMACEUTICAL CORPORATION

  公开号：EP0272914A2

  公开（公告）日：1988-06-29

  The synthesis of benzoxazinyl- and benzothiazinylpyridazinone compounds is described. The novel compounds are cardiotonic agents and inhibitors of phosphodiesterase. In addition, the compounds are useful as smooth muscle relaxants and bronchodilators.

  介绍了苯并恶嗪基和苯并噻嗪基哒嗪酮化合物的合成。 这些新型化合物是强心剂和磷酸二酯酶抑制剂。 此外，这些化合物还可用作平滑肌松弛剂和支气管扩张剂。
• 6-Benzoxazinylpyridazin-3-ones: potent, long-acting positive inotrope and peripheral vasodilator agents
  作者：Donald W. Combs、Marianne S. Rampulla、Stanley C. Bell、Dieter H. Klaubert、Alfonso J. Tobia、Robert Falotico、Barbara Haertlein、Constance Lakas-Weiss、John B. Moore

  DOI：10.1021/jm00163a061

  日期：1990.1

  A series of 6-benzoxazinylpyridazin-3-ones was prepared and evaluated for inhibition of cardiac phosphodiesterase (PDE) fraction III in vitro and for positive inotropic activity in vivo. 6-[3,4-Dihydro-3-oxo-1,4(2H)-benzoxazin-7-yl]-2,3,4,5-tetrahydro-5 - methylpyridazin-3-one (bemoradan) was found to be an extremely potent and selective inhibitor of canine PDE fraction III and a long-acting, potent, orally active inotropic vasodilator agent in various canine models. Additional benzoxazin-6-yl and -8-yl compounds were also prepared. Altering the pyridazinone substitution from the 6-position to the 7-position produced a 14-fold increase in the iv cardiotonic potency (ED50) from 77 to 5.4 micrograms/kg while substitution at the 8-position reduced potency. Methyl substitution at various sites in the molecule was also examined. Positive inotropic activity was maintained for between 8 and 24 h after a single oral dose (100 micrograms/kg) of bemoradan in dogs, thus making it one of the most potent and long-acting orally effective inotropes yet described. Bemoradan is currently under development as a cardiotonic agent for use in the management of congestive heart failure.
• SASTRY, C. V. REDDY;RAO, K. SRINIVASA;KRISHNAN, V. S. H.;RASTOGI, K.;JAIN+, INDIAN J. CHEM. B, 28,(1989) N0, C. 882-884
  作者：SASTRY, C. V. REDDY、RAO, K. SRINIVASA、KRISHNAN, V. S. H.、RASTOGI, K.、JAIN+

  DOI：——

  日期：——
• US4721784A
  申请人：——

  公开号：US4721784A

  公开（公告）日：1988-01-26
• US4766118A
  申请人：——

  公开号：US4766118A

  公开（公告）日：1988-08-23